CHEST NSCLC 2016

Non-small Cell Lung Cancer
Biomarker-driven targeted therapy of patients with NSCLC requires accurate diagnosis and staging. The pulmonary care team must acquire adequate biopsy tissue to enable histology, immunofluorescence and molecular biomarker testing.

Faculty: Momen M. Wahidi, MD, FCCP and W. Dean Wallace, MD

 

Download [pptx ยป 11MB]

Access other Therapeutic Areas: